{"schema_version":"secwatch.filing_event.v1","accession":"0000885725-23-000045","form_type":"8-K","ticker":"BSX","cik":"0000885725","company_name":"BOSTON SCIENTIFIC CORP","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.255395+00:00","generated_at":"2026-06-09T09:25:34.169365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Boston Scientific beats Q3 estimates; raises FY 2023 adjusted EPS guidance to $1.99-2.02","bullets":["Q3 net sales $3.527B (+11.2% reported, +10.2% organic); beat guidance of 8.5-10.5% reported and 7-9% organic.","GAAP EPS $0.34 (vs guidance $0.21-0.25); adjusted EPS $0.50 (vs guidance $0.46-0.48), up from $0.43 a year ago.","Cardiovascular sales $2.185B (+11.6% reported); MedSurg $1.341B (+10.6%); U.S. grew 8.5%, Asia-Pacific 14.8% reported.","FY 2023 guidance raised: organic sales growth ~11%; GAAP EPS $1.00-1.04; adjusted EPS $1.99-2.02 (prev. $1.94-1.98).","Announced agreement to acquire Relievant Medsystems (Intracept system) for vertebrogenic pain; terms not disclosed."],"urls":{"canonical":"https://secwatch.observer/filing/0000885725-23-000045","json":"https://secwatch.observer/filing/0000885725-23-000045.json","markdown":"https://secwatch.observer/filing/0000885725-23-000045.md","text":"https://secwatch.observer/filing/0000885725-23-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/0000885725-23-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/bsx-20231026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T09:25:34.169365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5cf748200fd1c673513e39efa4bbbc1a007a5dc3","claim":"BOSTON SCIENTIFIC CORP reported third quarter ended September 30, 2023 results: revenue $3.527 billion, net income $505 million or $0.34 per share, EPS $0.50.","evidence_excerpt":"Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational 1 basis and 10.2 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $505 million or $0.34 per share (EPS), compared to $174 million or $0.12 per share a year ago, and achieved adjusted 3 EPS of $0.50 for the period, compared to $0.43 a year ago.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/885725/000088572523000045/0000885725-23-000045-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$3.527 billion"},{"label":"Net income","value":"$505 million or $0.34 per share"},{"label":"EPS","value":"$0.50"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}